Glucocerebrosidase (GCase) is a lysosomal enzyme encoded by the GBA1 gene that catalyzes the hydrolysis of glucosylceramide to glucose and ceramide[1]. GCase activity in blood and CSF is an emerging biomarker for Parkinson's disease (PD) and Lewy body dementia (DLB), particularly in carriers of GBA1 mutations[2].
Loss of GCase function leads to Gaucher disease, and heterozygous GBA1 mutations are the most common genetic risk factor for PD, increasing risk by 5-20 fold depending on mutation severity[3].
| Property | Value |
|---|---|
| Full Name | Glucocerebrosidase |
| Abbreviation | GCase |
| Gene Symbol | GBA1 |
| UniProt ID | P04062 |
| Molecular Weight | ~63 kDa (dimer) |
| Subcellular Location | Lysosome |
| Sample Types | Plasma, Serum, CSF, Dried Blood Spot |
| Detection Method | Enzyme activity assay, Mass Spectrometry |
GCase serves as both an enzyme activity marker and a genetic risk indicator in neurodegeneration:
| Population | GCase Activity | Change |
|---|---|---|
| Healthy controls | 100% (baseline) | Reference |
| PD (non-carriers) | 70-85% | Reduced |
| PD (GBA1 carriers) | 40-60% | Significantly reduced |
| DLB | 65-80% | Reduced |
| Gaucher disease (heterozygote) | 35-50% | Severely reduced |
GCase activity is a diagnostic and progression biomarker for PD[4]:
In DLB, GCase indicates alpha-synuclein pathology[5]:
| Factor | Recommendation |
|---|---|
| Collection | EDTA plasma or serum; dried blood spots acceptable |
| Fasting | Overnight fast preferred (reduces lipid interference) |
| Centrifugation | Within 2 hours of collection |
| Storage | -80°C for long-term; avoid repeated freeze-thaw |
| Assay | Use standardized fluorescent substrate (luciferin) |
GCase is essential for glycosphingolipid metabolism[6]:
The relationship between GBA1 and PD involves several mechanisms:
| Therapeutic Approach | Mechanism | Status |
|---|---|---|
| Enzyme replacement | Recombinant GCase delivery | Under investigation |
| Small molecule chaperones | Ambroxol, migalastat stabilize GCase | Clinical trials |
| Substrate reduction | Eliglustat reduces glucosylceramide | Approved for Gaucher |
| Gene therapy | AAV-GBA1 delivery | Preclinical |
| ASO therapy | Modulate GBA1 expression | Preclinical |
Ambroxol is a GCase chaperone being repurposed for PD[7]:
The study of Glucocerebrosidase (Gcase) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Schapiro AN, et al. GCase activity as a biomarker for Parkinson's disease. Neurology. 2019. ↩︎
Gegg ME, et al. Glucocerebrosidase activity in Parkinson's disease. Brain. 2015. ↩︎
Atashrazm F, et al. GCase and alpha-synuclein in neurodegeneration. Cellular and Molecular Life Sciences. 2019. ↩︎
Liu G, et al. GCase mutations and Parkinson's disease risk. Annals of Neurology. 2017. ↩︎
Alcalay RN, et al. GCase in sporadic Parkinson's disease. Parkinsonism & Related Disorders. 2016. ↩︎
Woodard CL, et al. GCase substrate metabolism in the brain. Journal of Neurochemistry. 2019. ↩︎
Do J, et al. GCase targeting for Parkinson's disease therapy. Neurobiology of Disease. 2019. ↩︎